Healthcare technology company Evinova has entered an agreement with Quantum Leap Healthcare Collaborative (QLHC) to incorporate its remote patient monitoring (RPM) solution into the I-SPY 2.2 trial of various breast cancer treatments.
The study is claimed to be the largest and longest-running platform trial facilitating the framework for evaluating several therapeutic treatment arms in women with newly diagnosed, locally advanced breast cancer.
Go deeper with GlobalData
The RPM module is designed to warn healthcare professionals of early symptoms of interstitial lung disease (ILD), a potential adverse event associated with one of the study’s treatment arms.
This early warning system aims to enable healthcare professionals to triage subjects who require additional clinical assessment and take timely intervention measures according to established guidelines.
The solution also enables clinicians to monitor patients’ health status and adherence to treatment in real time.
QLHC and I-SPY trials founder Dr Laura Esserman said: “Using Evinova’s RPM solution in the study will help us, as providers, to identify and intervene early when ILD symptoms initially present.
“We are studying how this solution can improve the patient experience and minimise toxicity – that is what we all want to achieve.”
Evinova president Cristina Duran said: “With real-time alerts to both patients and sites, Evinova’s RPM solution for toxicity monitoring enables care teams to review and take proactive actions based on guidelines.
“At Evinova, we’re passionate about accelerating better health outcomes through technology like RPM that enables global life science leaders to overcome critical research challenges and deliver a better clinical trial experience for both sites and patients.”
In addition to pulmonary toxicity monitoring, Evinova’s RPM portfolio includes modules for stomatitis, gastrointestinal issues, and monitoring of oral thrush symptoms.
The company is developing additional modules to meet patients’ requirements and address the side effect profiles of various drugs.
